Trial Profile
A Phase 1/2, Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Jul 2019
Price :
$35
*
At a glance
- Drugs Staphylococcal-protein-A (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors Protalex
- 02 Jul 2019 Status changed from active, no longer recruiting to discontinued.
- 21 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 27 May 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.